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Abstract
Background: In around 50% of all human cancers the tumor suppressor p53 is mutated. It is generally assumed
that in the remaining tumors the wild-type p53 protein is functionally impaired. The two main inhibitors of p53,
hMDM2 (MDM2) and hMDMX (MDMX/MDM4) are frequently overexpressed in wild-type p53 tumors. Whereas the
main activity of hMDM2 is to degrade p53 protein, its close homolog hMDMX does not degrade p53, but it
represses its transcriptional activity. Here we study the role of hMDMX in the neoplastic transformation of human
fibroblasts and embryonic retinoblasts, since a high number of retinoblastomas contain elevated hMDMX levels.
Methods: We made use of an in vitro transformation model using a retroviral system of RNA interference and
gene overexpression in primary human fibroblasts and embryonic retinoblasts. Consecutive knockdown of RB and
p53, overexpression of SV40-small t, oncogenic HRasV12 and HA-hMDMX resulted in a number of stable cell lines
representing different stages of the transformation process, enabling a comparison between loss of p53 and
hMDMX overexpression. The cell lines were tested in various assays to assess their oncogenic potential.
Results: Both p53-knockdown and hMDMX overexpression accelerated proliferation and prevented growth
suppression induced by introduction of oncogenic Ras, which was required for anchorage-independent growth
and the ability to form tumors in vivo. Furthermore, we found that hMDMX overexpression represses basal p53
activity to some extent. Transformed fibroblasts with very high levels of hMDMX became largely resistant to the
p53 reactivating drug Nutlin-3. The Nutlin-3 response of hMDMX transformed retinoblasts was intact and
resembled that of retinoblastoma cell lines.
Conclusions: Our studies show that hMDMX has the essential properties of an oncogene. Its constitutive
expression contributes to the oncogenic phenotype of transformed human cells. Its main function appears to be
p53 inactivation. Therefore, developing new drugs targeting hMDMX is a valid approach to obtain new treatments
for a subset of human tumors expressing wild-type p53.
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Background
In approximately 50% of all human cancers mutations
are found in the TP53 gene, encoding the tumor sup-
pressor protein p53 [1,2], whereas it is assumed that in
tumors expressing wild-type p53 the tumor suppressing
activity of p53 is attenuated [3]. Normal, non-stressed
cells maintain relatively low p53 protein levels. Upon
various stress signals like DNA damage or oncogenic
stress, p53 is stabilized and activated. Activated p53
affects various processes, including cell cycle progres-
sion, DNA repair, senescence and apoptosis [4]. Two
main negative regulators of p53 are MDM2 and
MDMX, also called hMDM2 and hMDMX. MDM2, an
E3 ubiquitin ligase, inhibits p53 via poly-ubiquitination
[5] and by binding to p53’s N-terminus, thereby shield-
ing its transcription activation domain. Since the MDM2
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established [6]. The importance of MDM2 in p53 regu-
lation was best shown by the p53-dependent embryonic
lethality of MDM2 -/- mice [7,8]. Similarly, MDMX -/-
mice are embryonic lethal in a p53-dependent manner
[9-11], indicating that both MDM2 and MDMX fulfil an
essential, non-redundant function in p53-regulation.
Despite great structural similarities between MDM2 and
MDMX [12], including the RING finger domain needed
for MDM2 E3 ligase activity, MDMX has no detectable
E3 ligase activity. MDMX functions mostly by inhibiting
p53 activity through interaction with its transcription
activation domain [13,14]. Furthermore, MDMX and
MDM2 dimerize via their RING finger domains [15],
thereby stabilizing MDM2 and promoting its E3 ligase
activity towards p53 [16,17].
hMDM2 is overexpressed in 5-10% of all human
tumors, revealing hMDM2 as an oncogene [18]. Similar
observations were made regarding hMDMX. A study of
common tumor types showed increased hMDMX
mRNA expression in 20% of these tumors [19], and a
subset of gliomas contained hMDMX gene amplification
[20]. Furthermore, Ramos et al. showed upregulated or
aberrant hMDMX expression in a large number of
human tumor cell lines, mostly correlating with wild-
type p53 status [21]. A particularly high proportion of
retinoblastomas contain hMDMX gene amplification
[22]. hMDMX knockdown in p53 wild-type tumor cells
has been shown to induce p53-dependent growth inhibi-
tion [19,22].
The first evidence for direct oncogenic activity of
MDMX was provided by Danovi et al. [19]. MDMX
overexpression in early cultures of mouse embryonic
fibroblasts resulted in immortalization and neoplastic
transformation when combined with HRasV12 overex-
pression. This suggests that MDMX overexpression is
sufficient to inactivate the p53 tumor suppressor path-
way. However, such an oncogene function of hMDMX
has not yet been directly shown in human cells.
Human primary cells require a specific set of genetic
changes for neoplastic transformation. By expression of
the human Telomerase reverse transcriptase subunit
(hTERT), oncogenic HRasV12, and the early region of
SV40, encoding the viral large and small T antigens (LT
and st), primary human cells can be immortalized and
transformed. LT is needed to inactivate RB and p53,
since functional loss of both genes is required for tumor
formation [23,24]. By combining this transformation
model with specific RNA interference, the tumor-sup-
pressive functions of p14
ARF and p16
INK4A were assessed
by Voorhoeve and Agami [25]. They also showed that
directly targeting p53 and RB could replace LT expres-
sion. Here we use a retroviral system of RNA interfer-
ence and gene overexpression to establish an in vitro
transformation model for assessing the contribution of
hMDMX to the transformation of human primary cells.
Results
Generation of transformed human skin fibroblasts and
human embryonic retinoblasts, including hMDMX as a
potential oncogene
To investigate whether hMDMX c a nf u n c t i o na sa n
oncogene in the transformation of human primary cells,
we applied a previously described in vitro transforma-
tion model [25] to two different cell types: human fore-
skin fibroblasts (VH10) and human embryonic
retinoblasts (HER).
The generation of the VH10 transformation model is
depicted in Figure 1A. Sequential retroviral transduc-
tions resulted in a panel of stable polyclonal cell lines,
representing different stages of the transformation pro-
cess. This enabled a pair-wise comparison between
hMDMX overexpression and p53-knockdown. Stable
cell lines with shRB-HA-hMDMX, or shRB alone, could
not be established, suggesting that RB reduction is
growth limiting in these cells. Oncogenic HRasV12
without concomitant p53-knockdown or HA-hMDMX
overexpression induced a senescent-like crisis blocking
proliferation of most cells, followed by expansion of sin-
gle colonies. This suggests the occurrence of additional
selection bypassing the HRasV12-induced senescence.
RB knockdown was not sufficient to rescue HRasV12-
induced growth inhibition. Therefore, the cell lines
VH10-shRB-HRasV12 and VH10-HRasV12 could not be
established. We monitored the effectiveness of the trans-
ductions by western blotting (Figure 1B) and found
strong overexpression of hMDMX, somewhat increased
HRas levels and marked reductions of p53 and RB, cor-
relating with the respective transductions. Interestingly,
endogenous HRas level was slightly increased upon p53-
knockdown or hMDMX overexpression, correlating with
accelerated growth. HRasV12 has been reported to
induce p16-dependent senescence in human fibroblasts
[4,25,26]. Indeed, HRasV12-transformed as well as p53-
knockdown cells expressed higher p16 protein levels
(Figure 1B), although we observed no signs of senes-
cence. This suggests that during the transformation pro-
cess the pathway downstream of p16 is somehow
impaired. Alternatively, p53 inactivation may prevent
HRasV12-induced senescence, which was indeed
described for hMDMX overexpression [27].
For HER transformation, we initially used a compar-
able approach. However, HRasV12-transformed cells
could not be established without p53-knockdown or
HA-hMDMX overexpression, which prompted us to
modify the scheme (Figure 1C). Transformation of
HER-hTERT-shRB or HER-hTERT cells with an empty
puromycin vector and subsequent puromycin selection
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eventually stopped growing. This suggests that in HER
cells, in contrast to VH10, inactivation of p53 is essen-
tial for establishing immortalized cell lines. Protein
levels of RB, hMDMX, p53 and HRas correlated with
the applied transductions (Figure 1D), although the RB
depletion was less efficient in HA-hMDMX cells (lane 4
and 5). Similar to the observations in VH10 cells,
HRasV12 expression induced p16 protein levels in HER
cells. This did not affect growth of RB-knockdown cells,
whereas HER cells without RB-knockdown eventually
stopped proliferating upon HRasV12 overexpression.
Likely, HRasV12 activated a p16- and RB-dependent
mechanism resulting in growth suppression (also illu-
strated by large, flattened cells, Figure 2C), which could
not be rescued by p53-knockdown or hMDMX overex-
pression. Therefore, these cells could not be used in
further experiments.
hMDMX overexpression and p53-knockdown were
analyzed with qRT-PCR, showing approximately 90%
reduction of p53 and 10-fold increase of hMDMX
mRNA expression in VH10 cells (Table 1 and not
shown). Expression of p53 target genes p21, PUMA and
hMDM2-p2 was significantly decreased upon p53-
knockdown in VH10 and HER cells, and also hMDMX
overexpression slightly decreased basal levels of some of
these genes (Table 1). Reduced p21 protein levels upon
p53-knockdown (Figure 1B and 1D), in line with the
qRT-PCR data, indicate impaired basal p53 activity.
hMDMX overexpression did slightly reduce basal p21
protein levels in VH10 cells (Table 2), In addition, in
HA-hMDMX cells the protein levels of p53 were slightly
increased, most likely by protein stabilization.
Immunofluorescence analysis revealed abundant GFP
throughout the entire cell in all established HER and
VH10 cell lines, which confirmed SV40-st expression
(Additional File 1 Figure S1A and S1C).
Exogenous hMDMX showed mainly cytoplasmic loca-
lisation in VH10 cells, but nuclear hMDMX was also
observed (Additional File 1 Figure S1A). In HER cells,
the main localization was nuclear (Additional File 1
Figure S1B). High levels of cytoplasmic hMDMX were
reported to prevent p53 nuclear localization [28]. How-
ever, we found no alterations in p53 localization upon
hMDMX overexpression (Additional File 1 Figure S1B
and S1D). hMDM2 protein, irrespective of hMDMX
levels, was detected in the nucleus, although it could be
observed in the cytoplasm as well. The cytoplasmic sig-
nal of hMDM2 is relatively underrepresented since the
protein is diffused throughout the relatively large cyto-
plasmic surface, but is certainly present, as reported
before [29] (Additional File 1 Figure S1B and S1D).
Since p53 contributes to the maintenance of genomic
stability [4], the various cell lines were analyzed for
chromosomal abnormalities using COBRA-FISH [30].
Wild-type VH10hTERT cells (Additional File 2 Figure
S2A) showed a normal 46, XY karyogram in 20% of the
analyzed cells. The remaining cells harboured a Robert-
sonian translocation [31], which results in loss of the
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Figure 1 Generation of panels of transformed human skin
fibroblasts and human embryonic retinoblasts. A. Schematic
representation of transformation process. Primary human fibroblasts
(VH10) were immortalized with human Telomerase (hTERT). In
subsequent rounds of retroviral infection using the indicated
constructs, followed by selection, several stable cell lines were
created. B. Total cell extracts from all transformed fibroblast cell lines
were analyzed by immunoblotting with the indicated antibodies. C.
Human Embryonic Retinoblasts (HER) were similarly transformed
according to the scheme. D. Total cell extracts from all transformed
HER cell lines were analyzed by immunoblotting with the indicated
antibodies.
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Page 3 of 15short arms of two acrocentric chromosomes. As these
contain the ribosomal gene cassettes, this translocation
has no further consequences at the cellular level. The
observed rob(13;22) chromosome was lost during the
transformation process. The transformed VH10 cell
lines showed heterogeneous populations of mainly
diploid and chromosomal stable cells, with low percen-
tage random translocations or polyploidy. The HER cells
showed more chromosomal aberrations and transloca-
tions (Additional File 2 Figure S2B). Most notably, loss
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Figure 2 Transformation alters cell morphology and growth rate. Phase-contrast photographs of the transformed VH10 (A) and HER (C) cell
lines (10 × magnification, Olympus CKX41) showing morphology changes during the transformation process. Growth rates of VH10 (B) and HER
(D) cell lines were measured using WST-1 proliferation assays.
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Page 4 of 15of chromosome 13, harbouring the RB gene, was found
in four out of six cell lines. The fact that it was not
found in the HA-hMDMX and shRB-HA-hMDMX-
HRasV12 cell line suggests that loss of this chromosome
occurred independently in those four cell lines (see
Figure 1C for transformation scheme). Two unlinked
cell lines (shp53 and shRB-HA-hMDMX-HRasV12) lost
one X-chromosome, whereas loss of chromosome 22
and gain of chromosome 8 in shRB-shp53 and shRB-
shp53-HRasV12 is likely to have been passed on from
their shared parental cell line. In addition, several ran-
dom translocations and fusions were observed, however,
none was found in more than one cell line. In conclu-
sion, transformation of VH10 and HER cells did not
induce wide-spread genomic instability and aneuploidy.
Alterations in morphology and proliferation rate during
transformation process
Cell morphology changed during the transformation pro-
cess. Whereas normal VH10hTERT cells are extended,
fibroblastic cells aligning orderly in the dish, during the
sequential transformation stages the cells became appar-
ently smaller and rounder (Figure 2A). HRasV12 induced
a disordered way of growing and showed loss of contact
inhibition. hMDMX-overexpressing and p53-knockdown
cells showed similar morphology changes. Both shp53-
and HA-hMDMX cells obviously proliferated faster than
wild-type VH10hTERT cells, a property that was not
further enhanced by additional HRasV12 expression. This
was confirmed in short-term growth (WST-1) assays
(Figure 2B), suggesting that hMDMX overexpression is
sufficient to inhibit p53-dependent growth control, simi-
lar to p53-knockdown.
Morphology changes in transformed HER cells were
comparable to those observed in VH10 cells (Figure
2C). In addition, both p53-knockdown and hMDMX
overexpression accelerated growth as compared to wild-
type HER cells (Figure 2D). HRasV12 even further
enhanced growth rate in shRB-shp53 cells, but not in
shRB-HA-hMDMX cells.
Effect of hMDMX overexpression on anchorage-
independent growth
Anchorage-independent growth is a vital feature of
tumorigenic cells. Therefore, we investigated the growth
potential of the different cell lines in soft agar (Figure 3A).
Control VH10hTERT cells did not grow, but both
p53-knockdown and hMDMX overexpression induced
formation of some small colonies. HRasV12 expression
clearly increased the size and the number of colonies.
However, this was more pronounced in p53-knockdown
cells than in hMDMX-overexpressing cells. Interestingly,
hMDMX overexpression did not prevent the growth
inhibitory effect of Nutlin-3, in contrast to experiments
Table 1 mRNA expression levels in VH10 and HER cell
lines
VH10 p21 hMDM2-p2 PUMA
VH10 wt 1.00 ± 0.16 1.00 ± 0.17 1.00 ± 0.23
shp53 0.24 ± 0.03 0.20 ± 0.03 0.49 ± 0.11
HRasV12-shp53 0.15 ± 0.03 0.32 ± 0.07 0.44 ± 0.15
shRB-HRasV12-shp53 0.63 ± 0.11 0.41 ± 0.15 1.54 ± 0.32
HA-hMDMX 0.47 ± 0.09 0.61 ± 0.08 0.41 ± 0.08
HRasV12-HA-hMDMX 0.76 ± 0.12 1.05 ± 0.17 0.53 ± 0.14
shRB-HRasV12-HA-
hMDMX
1.05 ± 0.12 1.14 ± 0.15 0.28 ± 0.07
HER p21 hMDM2-p2 PUMA
HER wt 1.00 ± 0.16 1.00 ± 0.15 1.00 ± 0.19
shp53 0.11 ± 0.03 0.01 ± 0.01 0.46 ± 0.13
shRB-shp53 0.23 ± 0.05 0.02 ± 0.00 0.36 ± 0.06
shRB-HRasV12-shp53 0.05 ± 0.02 0.01 ± 0.00 0.15 ± 0.04
HA-hMDMX 1.51 ± 0.26 1.43 ± 0.28 0.67 ± 0.30
shRB-HA-hMDMX 1.01 ± 0.16 0.62 ± 0.13 0.34 ± 0.11
shRB-HRasV12-HA-
hMDMX
2.52 ± 0.70 0.61 ± 0.17 0.60 ± 0.17
Total RNA of each cell line was isolated and expression levels of the indicated
genes were determined by qRT-PCR and normalized for the housekeeping
genes CAPNS1 and TBP; levels are shown relative to wild-type cells.
Table 2 Protein levels, relative to untreated VH10 wt
cells, corrected for HAUSP expression
Cell line Nutlin-3 treatment
(h)
p53 p21 hMDM2
0 1.00 1.00 1.00
VH10 wt 6 4.96 6.68 82.32
24 7.82 11.16 149.60
0 0.35 0.20 0.27
shp53 6 0.87 0.65 0.30
24 1.25 2.26 4.54
0 0.28 0.03 0.33
HRasV12-shp53 6 0.30 0.09 0.78
24 0.44 0.33 0.74
0 0.45 1.01 2.51
shRB-HRasV12- shp53 6 0.49 1.24 4.55
24 0.74 2.85 9.17
0 6.99 0.56 0.87
HA-hMDMX 6 9.72 2.86 47.81
24 11.70 2.10 17.19
0 1.63 0.63 0.69
HRasV12-HA-hMDMX 6 4.13 2.88 36.75
24 5.01 3.07 29.42
0 1.07 1.45 2.79
shRB-HRasV12-HA-
hMDMX
6 2.38 5.37 132.80
24 1.76 4.28 79.91
Band intensities shown in figure 3B were quantified using the Odyssey 2.1
analysis software (LI-COR Biosciences) and the relative protein levels were
calculated using HAUSP expression as an internal control. Basal protein levels
in VH10 wild-type cells were set at 1.0.
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Figure 3 hMDMX overexpression promotes anchorage-independent growth and tumor growth in vivo. A, B. Various VH10hTERT and HER
cell lines were embedded in 0.3% agarose on a 0.6% agarose bottom-layer, with additional normal growth medium or growth medium
containing 10 μM Nutlin-3 on top of the agarose. Colony outgrowth was monitored and pictures were taken 18 days (VH10) and 4 weeks (HER)
after seeding. Representative pictures of several independent experiments are shown. C. Schedule for investigating in vivo growth of parental
and transformed VH10 cells using the shell-less chicken CAM model. At embryonic development day (EDD) 7, 2.5 million cells were grafted onto
a chicken CAM. Tumors were harvested at EDD17. D. Representative pictures of GFP-positive tumors, P-Histone-3 staining and vimentin staining.
E. Tumor volumes of VH10hTERT control (N = 5), shRB-HRasV12-shp53 (N = 4) and shRB-HRasV12-HA-hMDMX (N = 5). F. Quantification of the
number of mitotic (P-Histone-3 positive) cells. Statistical analysis was performed by one-way ANOVA followed by Bonferroni’s Multiple
Comparison Test. P < 0.05 was considered statistically significant.
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hMDMX cannot fully inhibit the function of p53 in soft
agar growth.
Untransformed HER cells did not grow at all in soft
agar, and neither hMDMX overexpression nor p53-
knockdown alone was able to induce colony formation
(not shown). Although additional RB knockdown
induced formation of very small colonies, only HRasV12
expression dramatically increased colony size and num-
ber (Figure 3B). Similar to the observations in VH10
cells, colony formation was more efficient in p53-knock-
d o w nc e l l st h a ni nh M D M X -overexpressing cells.
Furthermore, Nutlin-3 inhibited colony formation of
hMDMX-overexpressing cells, whereas p53-knockdown
cells were unaffected.
Role of hMDMX in tumorigenicity in vivo
We tested the in vivo tumorigenic potential of the trans-
formed VH10 cells by subcutaneous injection into Balb/
c nu/nu mice. Unfortunately, no tumor formation could
be detected. The lack of tumor growth could possibly be
explained by the immune response still present in nu/nu
mice; however, similar results were obtained in NOD/
S C I Dm i c e .T h e r e f o r e ,w es w i t c h e dt ot h es h e l l - l e s s
chick CAM assay [32] (Figure 3C-F). Ten days after
grafting both shRB-HRasV12-HA-hMDMX- and shRB-
HRasV12-shp53 tumors were significantly larger (4-5
fold) than those formed by wild-type VH10 cells (P <
0.05, Bonferroni’s Multiple Comparison Test; Figure 3D
left and E). Interestingly, the transformed cell lines
showed equal tumor volumes, indicating that hMDMX
overexpression and p53-knockdown have similar effects
on tumor growth. Moreover, tumors from the trans-
formed cells contained significantly (P < 0.05) more
mitotic cells than wild-type tumors as revealed with P-
Histone-3 staining, with no detectable difference
between hMDMX-overexpressing and p53-knockdown
cells (Figure 3D middle and 3F). Staining with fibroblast
marker vimentin showed the fibroblastic origin of the
tumors (Figure 3D right).
The in vivo growth capacity of transformed HER cells
was tested in a previously described murine model [33],
by injection into the anterior eye chamber of Balb/c nu/
nu mice. Both tested cell lines showed similar, but lim-
ited in vivo growth potential. The hMDMX-expressing
cells showed growth in 2/5 cases, but growth stopped
when the eye chamber was filled up to 50% with tumor
cells. The p53-knockdown cells started tumor growth in
4/5 cases, but stopped when the eye chamber was filled
up to 20% (2x), 30% (1x) or 50% (1x). Altogether, it is
clear that hMDMX overexpression promotes in vivo
tumor growth and in that respect largely mimics p53-
knockdown in the same cells.
hMDMX overexpression inhibits the Nutlin-3 induced p53
response in VH10 skin fibroblasts
We next investigated whether hMDMX overexpression
prevents p53 activation in VH10 cells. The various cell
lines were treated with the small-molecule p53-activator
Nutlin-3 [34]. Nutlin-3 reduced survival of normal
human fibroblasts (Figure 4A), whereas p53-knockdown
cells were not affected. hMDMX overexpression also
prevented Nutlin-3 induced growth inhibition. In wild-
type VH10hTERT cells, the Nutlin-3 response is marked
by increased p53, hMDM2 and p21 and decreased
hMDMX protein levels (Figure 4B). This response was
diminished upon p53-knockdown, reaching levels
slightly above basal expression in wild-type cells (Table
2). HA-hMDMX overexpression also attenuated the
induction of p53 and its target genes. Notably, exogen-
ous HA-hMDMX levels remained relatively high, despite
some Nutlin-3 induced degradation. Levels of the p53-
responsive transcripts of hMDM2-p2, p21 and PUMA
correlated with protein levels (Figure 4C). Furthermore,
hMDMX overexpression partially rescued the reduction
of the anti-apoptotic gene SURVIVIN by Nutlin-3 [35].
Table 3 shows fold changes of p53, hMDM2, hMDMX
and the p53 targets hMDM2-p2, p21, PUMA, GADD45-
alpha and SURVIVIN, for each cell line separately. As
expected, p53 and hMDMX mRNA levels did not signif-
icantly change upon Nutlin-3 treatment.
hMDMX overexpression in HER cells is not sufficient to
inhibit the Nutlin-3 induced p53 response
Similar to the observations in VH10, in HER cells
Nutlin-3 increased p53, hMDM2 and p21 and reduced
hMDMX protein levels, which was efficiently blocked by
p53-knockdown (Figure 5A). Surprisingly however,
hMDMX overexpression hardly rescued these effects.
Although at the mRNA level (Figure 5B) the inductions
of p53 targets hMDM2-p2, p21 and PUMA were indeed
slightly attenuated, this appeared to be insufficient to
prevent Nutlin-3 induced growth inhibition, as illu-
strated by reduced survival (Figure 5C) and S-phase
depletion (Figure 5D).
To explain the differences between the hMDMX-over-
expressing VH10 and HER cells in their Nutlin-3 response,
we compared protein and mRNA levels side-by-side (Fig-
ure 5E and 5F). Strikingly, HA-hMDMX was clearly higher
expressed in VH10 cells than in HER cells, while endogen-
ous p53, hMDM2 and p21 levels were comparable. As
Nutlin-3 not only binds hMDM2 but also hMDMX, albeit
with much lower affinity [22], the levels of hMDMX may
affect Nutlin-3 sensitivity. In HER cells, the remaining
hMDMX levels after Nutlin-3 treatment may not be suffi-
cient to prevent p53 activity. Importantly, we found that
hMDMX levels in transformed HER cells were comparable
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Figure 4 hMDMX overexpression inhibits Nutlin-3 mediated p53 activation in human fibroblasts. A. Various VH10hTERT cell lines were
continuously treated with 10 μM Nutlin-3 and proliferation was measured after 96 hours using a WST-1 assay. Relative cell numbers are
displayed as survival relative to untreated cells. B. Various VH10hTERT cell lines were treated for the indicated times with 10 μM Nutlin-3, and
protein levels were analyzed with immunoblotting using the indicated antibodies. C. qRT-PCR analysis of cells treated as in B. Expression levels of
hMDM2-p2, p21, PUMA and SURVIVIN are shown as the fold induction relative to untreated wild-type VH10 cells.
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(Figure 5G). We have previously shown that in these reti-
noblastoma cells p53 is inhibited via high hMDMX
expression, and that they are sensitive to Nutlin-3 [22].
These findings indicate that the transformed retinoblasts
provide a representative model for retinoblastoma.
T h er e s p o n s et oN u t l i n - 3m a ya l s ob ed e t e r m i n e db y
E2F1 activity, which activates p73. Kitagawa et al. [36]
reported that Nutlin-3-induced downregulation of E2F1
correlates with relative Nutlin-3 resistance, and they
suggested that cells lacking RB activity are much more
prone to entering Nutlin-3-induced apoptosis. There-
fore, we compared RB and E2F1 levels in a selected
panel of VH10 and HER cell lines (Figure 5E). As
reported before [37], Nutlin-3 decreased total and
hyper-phosphorylated (upper band) RB. However, the
amount of hypo-RB (lower band) was hardly affected.
Moreover, after Nutlin-3 treatment, the hypo-RB levels
in normal and RB-knockdown cells were comparable,
and the differences between VH10 and HER cells were
rather small. E2F1 reduction at the protein (Figure 5E)
and mRNA level (Additional File 3 Figure S3A, upper
panel) as observed in the parental VH10 and HER cells
was attenuated in the transformed cells. The mRNA
levels of the E2F1 target gene CDC25a followed a simi-
lar pattern. Nutlin-3 also reduced the expression of both
total p73 (Additional File 3 Figure S3A, lower panel)
and TA-p73 (not shown) in the parental cells. Strikingly,
basal p73 expression was strongly reduced upon trans-
formation. However, transformed VH10 and HER cells
showed comparable E2F1 regulation and p73 expression,
so this cannot explain the observed differences in
Nutlin-3 sensitivity. Therefore, these dissimilarities are
more likely the result of different HA-hMDMX levels.
hMDMX overexpression in VH10 cells also inhibited
p53 activation by 5-FU and etoposide on both mRNA
and protein level (Additional File 3 Figure S3B and
S3C), similar as observed with Nutlin-3 treatments.
However, reduced proliferation in response to these
drugs occurred mainly through p53-independent
Table 3 Fold induction mRNA per cell line after Nutlin-3 treatment
Cell line Nutlin-3
treatm
(h)
p53 p21 hMDM2 hMDM2-p2 hMDMX PUMA GADD45a SURVIVIN
VH10 wt 0 1.00 ± 0.19 1.00 ± 0.16 1.00 ± 0.16 1.00 ± 0.17 1.00 ± 0.16 1.00 ± 0.23 1.00 ± 0.38 1.00 ± 0.16
6 1.10 ± 0.18 9.36 ± 1.34 28.62 ± 5.40 43.93 ± 6.93 1.38 ± 0.21 4.90 ± 1.06 5.17 ± 1.45 0.90 ± 0.14
24 0.79 ± 0.18 11.98 ± 2.09 26.42 ± 5.42 66.60 ± 11.19 0.95 ± 0.16 4.49 ± 1.25 4.89 ± 1.79 0.02 ± 0.00
shp53 0 1.00 ± 0.09 1.00 ± 0.11 1.00 ± 0.25 1.00 ± 0.09 1.00 ± 0.09 1.00 ± 0.23 1.00 ± 0.11 1.00 ± 0.13
6 0.85 ± 0.17 2.24 ± 0.24 1.56 ± 0.31 4.26 ± 0.43 0.91 ± 0.17 1.84 ± 0.35 1.46 ± 0.28 1.18 ± 0.14
24 0.63 ± 0.54 5.36 ± 0.45 4.08 ± 0.92 9.46 ± 0.73 1.00 ± 0.12 3.29 ± 0.54 1.28 ± 0.12 0.85 ± 0.11
HRasV12-
shp53
0 1.00 ± 0.35 1.00 ± 0.27 1.00 ± 0.32 1.00 ± 0.28 1.00 ± 0.29 1.00 ± 0.41 1.00 ± 0.28 1.00 ± 0.23
6 0.81 ± 0.24 1.34 ± 0.33 1.29 ± 0.39 1.97 ± 0.56 1.09 ± 0.41 1.19 ± 0.40 1.14 ± 0.30 0.99 ± 0.22
24 0.84 ± 0.28 2.11 ± 0.50 1.44 ± 0.36 2.37 ± 0.66 1.18 ± 0.30 1.53 ± 0.47 1.37 ± 0.32 1.06 ± 0.22
shRB-
HRasV12-
shp53
0 1.00 ± 0.24 1.00 ± 0.18 1.00 ± 0.22 1.00 ± 0.48 1.00 ± 0.19 1.00 ± 0.18 1.00 ± 0.18 1.00 ± 0.18
6 0.88 ± 0.24 1.54 ± 0.30 1.16 ± 0.30 2.61 ± 0.97 1.22 ± 0.24 1.22 ± 0.54 1.49 ± 0.63 1.00 ± 0.20
24 0.98 ± 0.27 2.49 ± 0.67 1.68 ± 0.66 6.32 ± 2.59 1.18 ± 0.38 1.35 ± 0.35 1.76 ± 0.48 0.59 ± 0.16
HA-hMDMX 0 1.00 ± 0.17 1.00 ± 0.22 1.00 ± 0.03 1.00 ± 0.08 1.00 ± 0.34 1.00 ± 0.14 1.00 ± 0.09 1.00 ± 0.58
6 0.74 ± 0.23 4.14 ± 0.67 3.47 ± 1.26 11.83 ± 1.00 1.42 ± 0.36 3.05 ± 0.49 1.25 ± 0.58 1.52 ± 0.64
24 1.63 ± 0.25 6.86 ± 1.71 11.92 ± 1.36 18.14 ± 2.03 1.80 ± 0.58 5.45 ± 1.00 2.88 ± 0.93 0.48 ± 0.20
HRasV12-
HA-hMDMX
0 1.00 ± 0.14 1.00 ± 0.16 1.00 ± 0.16 1.00 ± 0.16 1.00 ± 0.22 1.00 ± 0.29 1.00 ± 0.14 1.00 ± 0.16
6 0.90 ± 0.16 6.78 ± 1.16 9.01 ± 1.83 17.33 ± 2.97 1.09 ± 0.22 3.09 ± 0.91 1.27 ± 0.21 0.79 ± 0.22
24 0.79 ± 0.10 10.38 ± 2.76 12.08 ± 1.58 26.21 ± 2.95 0.74 ± 0.11 3.50 ± 0.85 1.69 ± 0.19 0.26 ± 0.03
shRb-
HRasV12-
HA-hMDMX
0 1.00 ± 0.10 1.00 ± 0.05 1.00 ± 0.09 1.00 ± 0.07 1.00 ± 0.05 1.00 ± 0.26 1.00 ± 0.05 1.00 ± 0.06
6 1.04 ± 0.13 4.57 ± 0.46 6.46 ± 1.61 13.53 ± 2.08 1.01 ± 0.13 3.10 ± 0.63 1.73 ± 0.26 0.81 ± 0.13
24 0.99 ± 0.14 5.76 ± 0.92 6.55 ± 0.94 15.36 ± 2.04 0.96 ± 0.14 5.33 ± 1.27 1.71 ± 0.28 0.23 ± 0.03
VH10 cells were treated with 10 μM Nutlin-3 for the indicated times and analyzed using qRT-PCR. Expression was normalized for the housekeeping genes
CAPNS1 and TBP. The induction of mRNA expression upon Nutlin-3 treatment per cell line is shown for p53, p21, hMDM2, hMDM2-p2, hMDMX, PUMA,
GADD45alpha and SURVIVIN. For each cell line the basal mRNA expression is set at 1.0.
Lenos et al. Molecular Cancer 2011, 10:111
http://www.molecular-cancer.com/content/10/1/111
Page 9 of 15A
B
- +         - +     - +
HER     shp53   HA-hMDMX
hMDM2
p21
Ȗ-Tubulin
hMDMX
p53
hMDM2
p53
- +     - +          - +     - +
vector     HRasV12      vector   HRasV12
Nutlin-3
shRB-shp53 shRB-HA-hMDMX
Ȗ-Tubulin
p21
hMDMX
Nutlin-3
C
E
p53
p21
Vinculin
hMDMX
hMDM2
VH10hTneo HER
RRHX wt wt RRHX
- +        - +   - +         - +    Nutlin-3 
0
5
10
15
20
25
30
shRB-
HRasV12-
HA-hMDMX
wt wt
VH10 HER
f
o
l
d
 
i
n
d
u
c
t
i
o
n
 
p
r
o
t
e
i
n p53
hMDM2
p21
F
p53
hMDMX
RB
HER
  wt
 HER
RRHX
  Y79   Weri1
-   +          -   +    -   +    -    +    Nutlin-3
G
hMDM2
RB
E2F1 E2F1
Ȗ-Tubulin
shRB-
HRasV12-
HA-hMDMX
p21
0
2
4
6
8
10
12
14
16
18
HER vector shRB
R
e
l
a
t
i
v
e
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
untreated
24h Nutlin-3
PUMA
0
0.5
1
1.5
2
2.5
3
3.5
HER vector shRB
R
e
l
a
t
i
v
e
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
untreated
24h Nutlin-3
hMDM2-p2
0
10
20
30
40
50
60
70
80
HRasV12
-shp53
HRasV12
-HA-
hMDMX
shp53 HA-
hMDMX
shp53 HA-
hMDMX
HER vector shRB
R
e
l
a
t
i
v
e
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
untreated
24h Nutlin-3
WST-1 proliferation assay
0
0.2
0.4
0.6
0.8
1
1.2
HER vector shRB
R
e
l
a
t
i
v
e
 
S
u
r
v
i
v
a
l
 
Cells in S-phase
0
2
4
6
8
10
12
14
HER vector shRB
%
untreated
Nutlin-3
untreated
Nutlin-3
D
HRasV12
-shp53
HRasV12
-HA-
hMDMX
shp53 HA-
hMDMX
shp53 HA-
hMDMX
HRasV12
-shp53
HRasV12
-HA-
hMDMX
shp53 HA-
hMDMX
shp53 HA-
hMDMX
HRasV12
-shp53
HRasV12
-HA-
hMDMX
shp53 HA-
hMDMX
shp53 HA-
hMDMX
HRasV12
-shp53
HRasV12
-HA-
hMDMX
shp53 HA-
hMDMX
shp53 HA-
hMDMX
Figure 5 hMDMX overexpression in HER cells is not sufficient to prevent the Nutlin-3 induced p53-activation, which resembles
retinoblastoma cell lines. A. The various HER cell lines were treated with 10 μM Nutlin-3 for 24 hours, and protein levels were analyzed with
immunoblotting using the indicated antibodies. B. qRT-PCR analysis of cells treated as in A. Expression levels of hMDM2-p2, p21 and PUMA are
shown as the fold induction relative to untreated wild-type HER cells. C. The various HER cell lines were continuously treated with 10 μM Nutlin-
3 and proliferation was measured after 120 hours using a WST-1 assay. Relative cell numbers are displayed as survival relative to untreated cells.
D. Cells were treated with 10 μM Nutlin-3 for 24 hours and analyzed by flow cytometry. Percentages of cells in S-phase are displayed as
indicative for cell proliferation. E. Parental and shRB-HRasV12-HA-hMDMX (RRHX) transformed VH10 and HER cells were treated with 10 μM
Nutlin-3 for 24 hours and analyzed with immunoblotting using the indicated antibodies. F. Quantification of the indicated protein levels using
Odyssey 2.1 analysis software (LI-COR Biosciences) for at least two different exposures. Relative protein levels were calculated using Vinculin
expression as an internal control and indicated as fold induction relative to untreated cells. G. Parental and RRHX transformed HER cells and the
retinoblastoma cell lines Y79 and Weri1 were treated with 10 μM Nutlin-3 for 24 hours, and analyzed with immunoblotting using the indicated
antibodies.
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Page 10 of 15pathways, because neither p53-knockdown nor hMDMX
overexpression did not rescue the growth inhibitory
effect (Additional File 3 Figure S3D). Nevertheless,
FACS analysis showed different responses between wild-
type, hMDMX-overexpressing and p53-knockdown
VH10 cells (data not shown). Upon etoposide treatment,
wild-type and hMDMX-overexpressing cells showed a
two-fold reduction of G1 phase and an increased G2
fraction. The G2 arrest in p53-knockdown cells was
much more severe, with less than 10% remaining in G1.
5-FU induced S-phase accumulation and G2 reduction
in wild-type and HA-hMDMX expressing cells, whereas
p53-knockdown cells strongly accumulated in G1.
Discussion
In this study, we analyzed the putative oncogenic func-
tion of hMDMX in the neoplastic transformation of
normal human skin fibroblasts (VH10) and Human
Embryonic Retinoblasts (HER). We chose retinoblasts
since hMDMX is frequently overexpressed and/or
amplified in retinoblastoma development. Retinoblasto-
mas, like most other human tumors with increased
hMDMX levels, retain wild-type p53 [19-22], suggesting
that the oncogenic function of hMDMX is primarily
based upon p53 inhibition. After RB inactivation, E2F1
is activated resulting in elevated p14ARF levels, repres-
sion of hMDM2 and activation of p53. Since hMDMX
is not inhibited by p14ARF, hMDMX-overexpressing
cells escape the p53-mediated cell death [38].
Indeed, we find that constitutive expression of
hMDMX in foreskin fibroblasts functionally strongly
resembles p53-knockdown cells. In combination with
other defined genetic changes, hMDMX expression con-
tributes to neoplastic transformation. In transformed
cells, hMDMX overexpression reduces basal mRNA and
protein levels of p53 targets, with exception of hMDM2
protein levels which are increased most likely via
hMDMX-mediated stabilization. Vice versa, the expres-
sion of p53-repressed genes, like SURVIVIN, is increased.
The ultimately obtained transformed cells show ancho-
rage-independent growth, and can form tumors in an
in vivo model.
Similarly, hMDMX-expressing HER cells largely
resemble p53-knockdown HER cells regarding trans-
formed properties, although hMDMX is less able to
counteract the oncogenic HRas-induced growth inhibi-
tion, even in RB-knockdown cells. The ultimately
obtained transformed cells, with either hMDMX overex-
pression or p53-knockdown, show in vivo growth capa-
city, although limited.
Our results support the idea that the hMDMX overex-
pression, which is found in a subset of human tumors
[19-22], is an important step in the development of that
tumor, and that its main function is to inactivate p53.
Interestingly, recently two transgenic mouse models
have been described that widely overexpress MDMX
[39,40]. Surprisingly, the phenotypes were very different.
Whereas mice from the Lozano lab spontaneously devel-
oped tumors upon MDMX overexpression [39], no
spontaneous tumor formation nor cooperation with Eμ-
Myc-induced tumors was observed in the mice from the
Marine lab [40]. In both cases the MDMX-overexpres-
sing MEFs or thymocytes showed an attenuated p53
response upon Nutlin-3 and IR treatment, respectively,
suggesting the expression of a functional MDMX pro-
tein. It will be important to carefully examine these two
mouse models to understand the distinct phenotype.
This might teach us more about functions of MDMX in
tumorigenesis.
In line with these studies, we find that hMDMX over-
expression attenuates the Nutlin-3 mediated p53 activa-
tion and growth inhibition in skin fibroblasts. Nutlin-3
has a much lower affinity for hMDMX compared to
hMDM2 [22,41], so the effect of hMDMX overexpres-
sion is probably caused by direct p53 inhibition. Simi-
larly, hMDMX overexpression reduces p53 activation by
etoposide and 5-FU.
More strikingly, the hMDMX-overexpressing HER
cells are still sensitive to Nutlin-3. The p53-response is
hardly affected, both regarding regulation of p53 target
genes and inhibition of cell proliferation. This difference
with hMDMX-transformed VH10 cells is probably due
to the lower hMDMX levels in HER-hMDMX cells,
which are even further reduced by Nutlin-3. In that
respect, the Nutlin-3 response of the transformed reti-
noblasts resembles that of retinoblastoma cell lines. As
we have shown before, these retinoblastoma cell lines
are still sensitive to Nutlin-3 and even show an apopto-
tic response, despite high levels of hMDMX [22].
High hMDMX expression has been reported to
attenuate the Nutlin-3 response [42-44]. In a study by
Patton and colleagues [43], human embryonic lung
fibroblasts were transformed using hTERT, E1A, and
oncogenic Ras, with either hMDMX or hMDM2 overex-
pression, or p53-knockdown, and Nutlin-3 sensitivity
was assessed. They found that hMDMX overexpression,
in contrast to hMDM2, prevented p53 activation upon
Nutlin-3 treatment, which fits most of our data. Nutlin-
3 did not inhibit soft agar growth of hMDMX-overex-
pressing cells in their study. By contrast, we found par-
tial inhibition of soft agar growth by Nutlin-3, whereas
growth in a monolayer was not affected at all. Possibly,
in 3D additional stress is posed upon the cells, causing
super-activation of p53 that cannot be completely coun-
teracted by hMDMX proteins.
The discussed fibroblast models also show a different
Nutlin-3 response: IMR-90 cells entered apoptosis,
whereas in VH10 cells Nutlin-3 mainly inhibited cell
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Notably, IMR-90 cells are embryonic lung cells; embryo-
nic cells are less differentiated and can be more easily
transformed. Furthermore, Patton et al. used adenovirus
E1A for RB inactivation, but E1A proteins have addi-
tional growth affecting functions, including attenuation
of the p53 response by interacting with p300/CBP
[45,46]. Therefore, a clean appreciation of the effects of
hMDMX on the p53 response in the presence of E1A is
difficult.
Beside hMDMX levels, also other factors may be
involved in determining the outcome of Nutlin-3 treat-
ment. Kitagawa et al. [36] have shown that RB status
and E2F1 activity are important contributors. However,
we found only minor changes in E2F1 activity in our
model, which cannot explain the differences in Nutlin-3
sensitivity. Interestingly, the E2F1 target TA-p73 was
dramatically decreased upon transformation. This might
be a result of HRasV12 activity; oncogenic Ras has been
described to switch the expression from TA-p73 to the
antagonistic ΔN-p73, an important step during transfor-
mation. TA-p73 was reported to prevent anchorage-
independent growth via activation of KCNK1 [47]. How-
ever, since transformed fibroblasts as well as retinoblasts
express low levels of p73, this does not provide an
explanation for the differential Nutlin-3 responses.
Conclusions
In conclusion, we find that hMDMX overexpression can
replace loss of p53 during the transformation process of
human fibroblasts and embryonic retinoblasts. In addi-
tion, very high hMDMX levels, as observed in VH10
cells, can prevent p53 activation by Nutlin-3. However,
lower hMDMX levels like in the HER cells can no
longer inhibit p53 after Nutlin-3 treatment, because
hMDMX protein is mostly degraded by elevated
hMDM2 levels, as previously shown in other tumor cells
[48]. The Nutlin-3 response of the transformed HER
cells resembles that of retinoblastoma cell lines, indicat-
ing that this is a physiologically relevant model. A com-
bination therapy using Nutlin-3 and a specific hMDMX
inhibitor, possibly a low dose of a DNA damaging agent
leading to hMDMX degradation, might result in more
effective treatment of tumors expressing wild-type p53
and high levels of hMDMX.
Methods
Generation of stably transformed human cell lines
Primary human fibroblasts (VH10) and Human Embryo-
nic Retinoblasts (HER) were immortalized by introducing
human Telomerase (hTERT). Cells were maintained in
DMEM supplemented with 10% FBS, 1% glutamine, anti-
biotics, amino-acids, glucose and vitamins. Stably trans-
formed cell lines were generated in subsequent retroviral
infection rounds according to the transformation schemes
in Figure 1A and 1C. pRetroSuper-shRB-Hygro and pRS-
Hygro [25] were used for RB-knockdown or control cell
lines, followed by hygromycin selection (50 μg/ml).
pMSCV-blast-Ras or pMSCV-blast [25] were used for
HRasV12 overexpression or control cell lines, followed by
blasticidin selection (5 μg/ml). pBABE-HA-hMDMX-puro
or pRS-shp53-puro [25] were used for hMDMX overex-
pression or p53-knockdown, both combined with
pMSCV-GFP-st [25] for SV40-small-t expression, fol-
lowed by puromycin selection (0.5 μg/ml). Cell lines were
maintained under selection pressure.
Immunoblotting
Cells were lysed in Giordano 250 buffer (50 mM Tris-
HCl, pH 7.4, 250 mM NaCl, 0.1% Triton X-100, 5 mM
EDTA), with protease- and phosphatase inhibitors. Pro-
teins were separated by SDS-PAGE, transferred onto
polyvinyldene difluoride membranes (Immobilon-P,
Millipore) and incubated with the appropriate primary
(listed in Table 4) and HRP-conjugated secondary anti-
body (Jackson Laboratories). Bands were visualized by
enhanced chemiluminescence (Super Signal; Pierce).
Alternatively, membranes were incubated with second-
ary antibodies coupled to IRdye-680 and IRdye-800 near
Infrared dyes (LI-COR Biosciences), and analyzed with
the Odyssey Infrared Imager (LI-COR Biosciences). Sig-
nals were quantified using the Odyssey 2.1 analysis soft-
ware (LI-COR Biosciences).
Immunofluorescence
Cells were fixed with 4% paraformaldehyde for 10 min,
permeabilized with 0.2% Triton X-100 for 10 min, blocked
with 5% Normal Goat Serum (NGS) for 1 hour and incu-
bated with primary antibodies for 1.5 hours and anti-
mouse-Rhodamine secondary antibody (Jackson Labora-
tories) for 30 min. Coverslips were mounted onto micro-
scope slides using DAPI-DABCO mounting solution.
RNA isolation, qRT-PCR
RNA was isolated using the SV Total RNA isolation kit
( P r o m e g a ,M a d i s o n ,W I ) .c D N Aw a ss y n t h e s i z e du s i n g
1.0 μg RNA in Reverse Transcriptase reaction mixture
(Promega). Samples were analyzed in triplicate using
SYBR Green mix (Roche Biochemicals, Indianapolis, IN)
in a 7900 ht Fast Real-Time PCR System (Applied Bio-
systems, Foster City, CA). For normalization the geo-
metric mean of at least two housekeeping genes was
used. Primer sequences are available in Table 5.
Growth assay, soft agar assay
For growth assays, 1000 cells were seeded in triplicate in
96-wells plates; treatments were started 24 hours after
seeding. Cells were incubated with WST-1 reagent
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measured in a microplate reader (Victor3 Multilabel
Counter 1420-042, Perkin-Elmer).
Soft agar assays were performed in 96-well plates
(VH10) or 6-well plates (HER) coated with a 0.6% agar-
ose bottom-layer. Per well, 5000 VH10 or 20.000 HER
cells were seeded in 0.3% agarose. Colony outgrowth
was monitored (10 × magnification, Olympus CKX41)
and pictures were taken at several time points.
Flow cytometry
Cells were harvested, washed with PBS and fixed ice-
cold 70% ethanol. Cells were washed in PBS and incu-
bated in PBS containing 50 μg/ml propidium iodide and
50 μg/ml RNase. Flow cytometry was performed in a
BD LSR II system (BD Biosciences).
Cytogenetic methods and combined binary ratio
fluorescence in situ hybridization (COBRA-FISH)
Culturing, harvest conditions and karyotyping were per-
formed according to standard protocols [49]. Slides with
metaphase chromosomes were hybridized using a multi-
color FISH approach. Staining, digital imaging, and ana-
lysis were performed as described previously [30].
Hybridizations with individual libraries labeled with sin-
gle fluorochromes were used to confirm the detected
rearrangements. Chromosomal breakpoints were
assigned by using inverted images counterstained with
4’,6-diamidino-2-phenylindole (DAPI; Downers Grove,
IL) together with the information derived from the
short- and long-arm specific hybridization during
COBRA-FISH. Karyotypes were described according to
ISCN 2009.
Shell-less Chicken Chorioallantoic Membrane (CAM) assay
Fertilised chicken eggs were incubated at 37°C in humi-
dified atmosphere. After 4 days they were cracked open
into plastic dishes. At day 7, two-and-half million cells
transduced with turbo-GFP lentiviral construct
(SHC003, Sigma-Aldrich) were mixed with 50 μl base-
ment membrane matrix (BD Biosciences) and grafted
onto the CAM. At day 17, tumors with surrounding
CAM were removed and the size was measured. GFP-
positive tumors were photographed using a fluorescence
stereomicroscope. Tumors were embedded in paraffin,
sectioned and stained with anti-Vimentin, clone V9
(Santa Cruz) and anti-phospho-Histone-3 (Upstate,
Table 4 List of used antibodies
Protein Name/cat. # Company
hMDMX A300-287A Bethyl Laboratories, Montgomery TX,
USA
hMDMX 6B1A [50]
HA-tag HA.11 Covance, Princeton, New Jersey, USA
HA-tag ab9110 Abcam, Cambridge, UK
p53° DO-1/sc-126 Santa Cruz Biotechnology, Santa Cruz,
CA, USA
p53° PAb 1801/sc-
98
Santa Cruz Biotechnology, Santa Cruz,
CA, USA
p53 FL-393 Santa Cruz Biotechnology, Santa Cruz,
CA, USA
hMDM2
*/MDM2
4B2 [51]
hMDM 2 * SMP14 sc-
6965
Santa Cruz Biotechnology, Santa Cruz,
CA, USA
p21 CP74/05-655 Upstate Biotechnology, Lake Placid, NY,
USA
RB G3-245/
554136
BD Pharmingen, Franklin Lakes, New
Jersey, USA
HRas Y13-259 [52]
HAUSP/USP7 A300-033A Bethyl Laboratories, Montgomery TX,
USA
HAUSP/USP7 7G9 [53]
p21 CP74/05-655 Upstate Biotechnology, Lake Placid, NY,
USA
g-tubulin GTU-88/
T6557
Sigma-Aldrich, St Louis, MO, USA
Antibodies used in this study are listed in table 4, together with name or
category number and the name of the company. For detection of human p53
we used a mix of DO-1 and 1801 (°), for detection of human Hdm2 we used a
mix of 4B2 and SMP14 (*).
Table 5 Primer sequences
hMDM2-P2 Fw 5’-acgcacgccactttttctct- 3’
hMDM2-P2 Rv 5’-tccgaagctggaatctgtgag- 3’
P53 Fw 5’-ctctccccagccaaagaagaa- 3’
P53 Rv 5’-tccaaggcctcattcagctct- 3’
hMDMX Fw 5’-aggtgcgcaaggtgaaatgt- 3’
hMDMX Rv 5’-ccatatgctgctcctgctgat- 3’
PUMA Fw 5’-gacctcaacgcacagta- 3’
PUMA Rv 5’-ctaattgggctccatct- 3’
p21 Fw 5’-agcagaggaagaccatgtgga- 3’
p21 Rv 5’-aatctgtcatgctggtctgcc- 3’
SURVIVIN Fw 5’-gagacagaatagagtgatagg- 3’
SURVIVIN Rv 5’-gacagatgtgaaggttgg- 3’
GADD45A Fw 5’-gcgacctgcagtttgcaata- 3’
GADD45A Rv 5’-atcccccaccttatccatcct- 3’
CAPNS1 Fw 5’-atggttttggcattgacacatg- 3’
CAPNS1 Rv 5’-gcttgcctgtggtgtcgc- 3’
TBP Fw 5’-cacgaaccacggcactgatt- 3’
TBP Rv 5’-ttttcttgctgccagtctggac- 3’
RPS11 Fw 5’-aagcagccgaccatctttca- 3’
RPS11 Rv 5’-cgggagcttctccttgcc- 3’
SRPR Fw 5’-cattgcttttgcacgtaaccaa- 3’
SRPR Rv 5’-attgtcttgcatgcggcc- 3’
CDC25A Fw 5’-ctccgagtcaacagattcagg- 3’
CDC25A Rv 5’-ttcaaggttttctttactgtccaa- 3’
Sequences of qRT-PCR primers used in this study.
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Page 13 of 15Millipore). Percentage of proliferating cells was calcu-
lated by quantifying phospho-Histone-3 positive nuclei
of on average 500 nuclei from 5 random pictures per
sample.
Additional material
Additional file 1: Figure S1. Overexpressed HA-hMDMX is localised
both nuclear and cytoplasmic and does not alter p53 and hMDM2
localisation. Localisation of hMDMX, hMDM2 and p53 in various VH10 (A,
B) and HER (C, D) cell lines was determined by immunofluorescence
using the indicated antibodies. DAPI staining was used to visualise
nuclei, GFP signal represents SV-40 small-t expression.
Additional file 2: Figure S2. Karyotyping of VH10 and HER cell lines.
Karyotypes of transformed VH10 (A) and HER (B) cell lines using
combined binary ratio labeling-fluorescence in situ hybridization (COBRA-
FISH). Representative karyograms after COBRA-FISH hybridization are
shown for each cell line.
Additional file 3: Figure S3. hMDMX overexpression inhibits p53
response but does not rescue the growth inhibition induced by 5-fluoro-
uracil or etoposide in human fibroblasts. A. The indicated VH10 and HER
cell lines were treated with 10 μM Nutlin-3 for 24 hours and analyzed
with qRT-PCR. Expression levels of E2F1, CDC25a (upper panel) and p73
(lower panel) were normalized for housekeeping genes RPS11 and
CAPNS1. B. Indicated VH10 cell lines were treated for 24 hours with 25
μM 5-FU, 5 μM etoposide or mock treated, and analyzed with qRT-PCR.
Expression levels of hMDM2-p2 and p21 were normalized for
housekeeping genes CAPNS1 and SRPR. C. Protein levels of cells treated
as in B were analyzed with immunoblotting using the indicated
antibodies. D. Cell growth was monitored using WST-1 proliferation
assays. 24 hours after seeding the cells were treated for 24 hours with
the indicated drugs. Cell proliferation was measured at day 0, 2 and 4
after treatment.
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